Denne side blev automatisk oversat, og nøjagtigheden af oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

5. marts 2015 opdateret af: Southwest Oncology Group

A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may help chemotherapy drugs kill more cancer cells by making them more sensitive to the drugs.

PURPOSE: Phase II trial to study the effectiveness of PSC 833, daunorubicin, and cytarabine in treating older patients who have newly diagnosed acute myeloid leukemia.

Studieoversigt

Status

Afsluttet

Betingelser

Leukæmi

Intervention / Behandling

Detaljeret beskrivelse

OBJECTIVES: I. Determine the safety and efficacy of daunorubicin and cytarabine by continuous infusion and PSC 833 in patients over age 56 with newly diagnosed acute myeloid leukemia. II. Determine the frequency and severity of toxicities of this regimen in these patients. III. Determine the frequency and prognosis of functional and phenotypic P-glycoprotein expression, cytogenetics, and pharmacokinetics in this population.

OUTLINE: This is a multicenter study. Patients receive induction chemotherapy consisting of PSC 833 IV over 2 hours on day 1, then continuously for 96 hours; daunorubicin IV continuously on days 1-3; and cytarabine IV continuously on days 1-7. Filgrastim (G-CSF) or sargramostim (GM-CSF) is administered subcutaneously (SQ) or IV beginning on day 15 and continuing until blood counts recover or day 21. If patients do not achieve complete remission after one course, a second course is administered. Patients who achieve A1 bone marrow, B1 peripheral blood, and C1 extramedullary disease status after 1 or 2 courses of induction chemotherapy proceed to consolidation therapy, which begins upon recovery from induction therapy. Consolidation therapy consists of PSC 833 over 2 hours on day 1, daunorubicin IV over 1-5 minutes on days 1 and 2, and cytarabine IV continuously on days 1-5. Treatment repeats for a total of 2 courses. Patients are followed every 6 months for 2 years and then annually for 3 years.

PROJECTED ACCRUAL: A total of 20-55 patients will be accrued for this study within 8-9 months.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

Fase

Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Canada
- British Columbia
  - Vancouver, British Columbia, Canada, V5Z 4E6
    - BC Cancer Agency
Forenede Stater
- Alabama
  - Mobile, Alabama, Forenede Stater, 36688
    - MBCCOP - University of South Alabama
- Arizona
  - Phoenix, Arizona, Forenede Stater, 85006-2726
    - CCOP - Greater Phoenix
  - Phoenix, Arizona, Forenede Stater, 85012
    - Veterans Affairs Medical Center - Phoenix (Hayden)
  - Tucson, Arizona, Forenede Stater, 85724
    - Arizona Cancer Center
  - Tucson, Arizona, Forenede Stater, 85723
    - Veterans Affairs Medical Center - Tucson
- Arkansas
  - Little Rock, Arkansas, Forenede Stater, 72205
    - University of Arkansas for Medical Sciences
  - Little Rock, Arkansas, Forenede Stater, 72205
    - Veterans Affairs Medical Center - Little Rock (McClellan)
- California
  - Long Beach, California, Forenede Stater, 90822
    - Veterans Affairs Medical Center - Long Beach
  - Los Angeles, California, Forenede Stater, 90033-0800
    - USC/Norris Comprehensive Cancer Center
  - Los Angeles, California, Forenede Stater, 90095-1781
    - Jonsson Comprehensive Cancer Center, UCLA
  - Los Angeles, California, Forenede Stater, 91010
    - Beckman Research Institute, City of Hope
  - Martinez, California, Forenede Stater, 94553
    - Veterans Affairs Outpatient Clinic - Martinez
  - Oakland, California, Forenede Stater, 94609-3305
    - CCOP - Bay Area Tumor Institute
  - Orange, California, Forenede Stater, 92868
    - Chao Family Comprehensive Cancer Center
  - Sacramento, California, Forenede Stater, 95817
    - University of California Davis Medical Center
  - San Francisco, California, Forenede Stater, 94121
    - Veterans Affairs Medical Center - San Francisco
  - San Francisco, California, Forenede Stater, 94115-0128
    - UCSF Cancer Center and Cancer Research Institute
  - Santa Rosa, California, Forenede Stater, 95403
    - CCOP - Santa Rosa Memorial Hospital
  - Travis Air Force Base, California, Forenede Stater, 94535
    - David Grant Medical Center
- Colorado
  - Denver, Colorado, Forenede Stater, 80220
    - Veterans Affairs Medical Center - Denver
  - Denver, Colorado, Forenede Stater, 80262
    - University of Colorado Cancer Center
- Georgia
  - Atlanta, Georgia, Forenede Stater, 30342-1701
    - CCOP - Atlanta Regional
- Hawaii
  - Honolulu, Hawaii, Forenede Stater, 96813
    - Cancer Research Center of Hawaii
- Illinois
  - Decatur, Illinois, Forenede Stater, 62526
    - CCOP - Central Illinois
  - Hines, Illinois, Forenede Stater, 60141
    - Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
  - Maywood, Illinois, Forenede Stater, 60153
    - Loyola University Medical Center
- Kansas
  - Kansas City, Kansas, Forenede Stater, 66160-7357
    - University of Kansas Medical Center
  - Wichita, Kansas, Forenede Stater, 67214-3882
    - CCOP - Wichita
  - Wichita, Kansas, Forenede Stater, 67218
    - Veterans Affairs Medical Center - Wichita
- Kentucky
  - Lexington, Kentucky, Forenede Stater, 40511-1093
    - Veterans Affairs Medical Center - Lexington
  - Lexington, Kentucky, Forenede Stater, 40536-0084
    - Albert B. Chandler Medical Center, University of Kentucky
- Louisiana
  - New Orleans, Louisiana, Forenede Stater, 70112
    - Tulane University School of Medicine
  - New Orleans, Louisiana, Forenede Stater, 70112
    - MBCCOP - LSU Medical Center
  - New Orleans, Louisiana, Forenede Stater, 70112
    - Veterans Affairs Medical Center - New Orleans
  - Shreveport, Louisiana, Forenede Stater, 71130-3932
    - Louisiana State University Health Sciences Center - Shreveport
  - Shreveport, Louisiana, Forenede Stater, 71130
    - Veterans Affairs Medical Center - Shreveport
- Massachusetts
  - Boston, Massachusetts, Forenede Stater, 02118
    - Boston Medical Center
  - Jamaica Plain, Massachusetts, Forenede Stater, 02130
    - Veterans Affairs Medical Center - Boston (Jamaica Plain)
- Michigan
  - Ann Arbor, Michigan, Forenede Stater, 48109-0752
    - University Of Michigan Comprehensive Cancer Center
  - Ann Arbor, Michigan, Forenede Stater, 48105
    - Veterans Affairs Medical Center - Ann Arbor
  - Detroit, Michigan, Forenede Stater, 48201
    - Barbara Ann Karmanos Cancer Institute
  - Detroit, Michigan, Forenede Stater, 48202
    - Henry Ford Hospital
  - Detroit, Michigan, Forenede Stater, 48201-1932
    - Veterans Affairs Medical Center - Detroit
  - Grand Rapids, Michigan, Forenede Stater, 49503
    - CCOP - Grand Rapids Clinical Oncology Program
  - Southfield, Michigan, Forenede Stater, 48075-9975
    - Providence Hospital - Southfield
- Mississippi
  - Biloxi, Mississippi, Forenede Stater, 39531-2410
    - Veterans Affairs Medical Center - Biloxi
  - Jackson, Mississippi, Forenede Stater, 39216-4505
    - University of Mississippi Medical Center
  - Jackson, Mississippi, Forenede Stater, 39216
    - Veterans Affairs Medical Center - Jackson
  - Keesler AFB, Mississippi, Forenede Stater, 39534-2576
    - Keesler Medical Center - Keesler AFB
- Missouri
  - Kansas City, Missouri, Forenede Stater, 64128
    - Veterans Affairs Medical Center - Kansas City
  - Kansas City, Missouri, Forenede Stater, 64131
    - CCOP - Kansas City
  - Saint Louis, Missouri, Forenede Stater, 63110-0250
    - St. Louis University Health Sciences Center
  - Saint Louis, Missouri, Forenede Stater, 63141
    - CCOP - St. Louis-Cape Girardeau
  - Springfield, Missouri, Forenede Stater, 65807
    - CCOP - Cancer Research for the Ozarks
- Montana
  - Billings, Montana, Forenede Stater, 59101
    - CCOP - Montana Cancer Consortium
- New Mexico
  - Albuquerque, New Mexico, Forenede Stater, 87108-5138
    - Veterans Affairs Medical Center - Albuquerque
  - Albuquerque, New Mexico, Forenede Stater, 87131
    - MBCCOP - University of New Mexico HSC
- New York
  - Brooklyn, New York, Forenede Stater, 11209
    - Veterans Affairs Medical Center - Brooklyn
  - New York, New York, Forenede Stater, 10032
    - Herbert Irving Comprehensive Cancer Center
- Ohio
  - Cincinnati, Ohio, Forenede Stater, 45219
    - Barrett Cancer Center, The University Hospital
  - Cincinnati, Ohio, Forenede Stater, 45220-2288
    - Veterans Affairs Medical Center - Cincinnati
  - Cleveland, Ohio, Forenede Stater, 44195
    - Cleveland Clinic Cancer Center
  - Columbus, Ohio, Forenede Stater, 43206
    - CCOP - Columbus
  - Dayton, Ohio, Forenede Stater, 45428
    - Veterans Affairs Medical Center - Dayton
  - Kettering, Ohio, Forenede Stater, 45429
    - CCOP - Dayton
- Oklahoma
  - Oklahoma City, Oklahoma, Forenede Stater, 73104
    - Oklahoma Medical Research Foundation
  - Oklahoma City, Oklahoma, Forenede Stater, 73104
    - Veterans Affairs Medical Center - Oklahoma City
- Oregon
  - Portland, Oregon, Forenede Stater, 97201-3098
    - Oregon Cancer Center at Oregon Health Sciences University
  - Portland, Oregon, Forenede Stater, 97207
    - Veterans Affairs Medical Center - Portland
  - Portland, Oregon, Forenede Stater, 97213
    - CCOP - Columbia River Program
- South Carolina
  - Greenville, South Carolina, Forenede Stater, 29615
    - CCOP - Greenville
  - Spartanburg, South Carolina, Forenede Stater, 29303
    - CCOP - Upstate Carolina
- Texas
  - Dallas, Texas, Forenede Stater, 75216
    - Veterans Affairs Medical Center - Dallas
  - Dallas, Texas, Forenede Stater, 75235-9154
    - Simmons Cancer Center - Dallas
  - Fort Sam Houston, Texas, Forenede Stater, 78234
    - Brooke Army Medical Center
  - Galveston, Texas, Forenede Stater, 77555-1329
    - University of Texas Medical Branch
  - Houston, Texas, Forenede Stater, 77030
    - University of Texas - MD Anderson Cancer Center
  - Lubbock, Texas, Forenede Stater, 79423
    - Texas Tech University Health Science Center
  - San Antonio, Texas, Forenede Stater, 78284-7811
    - University of Texas Health Science Center at San Antonio
  - San Antonio, Texas, Forenede Stater, 78284
    - Veterans Affairs Medical Center - San Antonio (Murphy)
  - Temple, Texas, Forenede Stater, 76504
    - Veterans Affairs Medical Center - Temple
  - Temple, Texas, Forenede Stater, 76508
    - CCOP - Scott and White Hospital
- Utah
  - Salt Lake City, Utah, Forenede Stater, 84132
    - Huntsman Cancer Institute
  - Salt Lake City, Utah, Forenede Stater, 84148
    - Veterans Affairs Medical Center - Salt Lake City
- Vermont
  - Bennington, Vermont, Forenede Stater, 05201
    - CCOP - Southwestern Vermont Regional Cancer Center
- Washington
  - Seattle, Washington, Forenede Stater, 98101
    - CCOP - Virginia Mason Research Center
  - Seattle, Washington, Forenede Stater, 98104
    - Swedish Cancer Institute
  - Seattle, Washington, Forenede Stater, 98108
    - Veterans Affairs Medical Center - Seattle
  - Tacoma, Washington, Forenede Stater, 98405-0986
    - CCOP - Northwest

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

56 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

DISEASE CHARACTERISTICS: Morphologically confirmed acute myeloid leukemia (AML) No M3 AML or blastic phase chronic myelogenous leukemia Must be registered on protocols SWOG-9007 and SWOG-9910

PATIENT CHARACTERISTICS: Age: 56 and over Performance status: Zubrod 0-3 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT/SGPT no greater than 4 times ULN Renal: Creatinine no greater than 1.5 times ULN Creatinine clearance greater than 40 mL/min Cardiovascular: LVEF at least 50% by MUGA or echocardiogram No unstable cardiac arrhythmias or angina Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except: Adequately treated basal cell or squamous cell skin cancer Carcinoma in situ of the cervix Adequately treated stage I or II cancer in complete remission

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for acute leukemia Prior hydroxyurea to control high cell counts allowed At least 30 days since prior low dose cytarabine (less than 100 mg/m2/day) for myelodysplastic syndrome and recovered Single dose of prior or concurrent (with induction chemotherapy) intrathecal chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Primært formål: Behandling
Tildeling: Ikke-randomiseret
Interventionel model: Enkelt gruppeopgave
Maskning: Ingen (Åben etiket)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål	Tidsramme
response Tidsramme: after induction therapy is completed	after induction therapy is completed

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Southwest Oncology Group

Samarbejdspartnere

National Cancer Institute (NCI)

Efterforskere

Studiestol: Thomas R. Chauncey, MD, PhD, VA Puget Sound Health Care System

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. februar 2000

Primær færdiggørelse (Faktiske)

1. maj 2001

Studieafslutning (Faktiske)

1. marts 2006

Datoer for studieregistrering

Først indsendt

28. januar 2000

Først indsendt, der opfyldte QC-kriterier

17. juni 2004

Først opslået (Skøn)

18. juni 2004

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

6. marts 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. marts 2015

Sidst verificeret

1. marts 2015

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

S9918 (Anden identifikator: SWOG)
U10CA032102 (U.S. NIH-bevilling/kontrakt)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .